Glucagon-like peptide-1 7-36 amide (GLP-1) has been postulated to be the primary hormonal mediator of the enteroinsular axis but evidence has been indirect. The discovery of exendin (9-39), a GLP-1 receptor antagonist, allowed this to be further investigated. The IC5o for GLP-1 receptor binding, using RIN 5AH fl-cell membranes, was found to be 0.36 nmol/l for GLP-1 and 3.44 nmol/l for exendin (9-39). There was no competition by exendin (9-39) at binding sites for glucagon or related peptides. In the anaesthetized fasted rat, insulin release after four doses of GLP-1 (0.1, 0.2, 0.3, and 0.4 nmol/kg) was tested by a 2-min intravenous infusion. Exendin (9-39) (1.5, 3.0, and 4.5 nmol/kg) was administered with GLP-1 0.3 nmol/kg, or saline, and only the highest dose fully inhibited insulin release. Exendin (9-39) at 4.5 nmol/kg had no effect on glucose, arginine, vasoactive intestinal peptide or glucose-dependent insulinotropic peptide stimulated insulin secretion. Postprandial insulin release was studied in conditioned conscious rats after a standard meal. Exendin (9-39) (0.5 nmol/kg) considerably reduced postprandial insulin concentrations, for example by 48% at 15 min (431±21 pmol/ I saline, 224±32 pmol/l exendin, P < 0.001). Thus, GLP-1 appears to play a major role in the entero-insular axis. (J. Clin. Invest. 1995.95:417-421.)
Introduction
Glucose ingestion results in a greater elevation in plasma insulin levels than an equivalent plasma glucose concentration attained by the intravenous route. The augmented response to oral glucose defines the entero-insular axis, also referred to as the glucoincretin effect. It is thought to be mediated in part by the release of gut hormones into the blood which potentiate glucoseinduced ,Q-cell insulin secretion (1) (2) (3) . A number of gut peptides have been suggested as being insulinotropic, such as secre-tin, gastrin-releasing peptide, vasoactive intestinal peptide (VIP),' and cholecystokinin (1) (2) (3) . However, these peptides display their insulinotropic activity only at pharmacological plasma concentrations. The most likely physiological glucoincretins that have been characterized are glucose-dependent insulinotropic polypeptide (GIP) (4, 5) and GLP-l 7-36NH2 (GLP-1) (6) (7) (8) (9) .
GLP-1 is a member of an extended family of bioactive peptides, including glucagon, GIP, pituitary adenylate cyclase activating polypeptide (PACAP) and VIP, all of which have closely related amino acid sequences and can stimulate insulin secretion. The endocrine L cells of the intestine are the major site of synthesis of GLP-1, (10, 11) , which is released principally in response to luminal carbohydrate and long chain fatty acids ( 12) . In man, the infusion of GLP-1 to achieve the plasma GLP-1 concentrations seen after a meal, increases plasma insulin concentrations and decreases plasma glucagon and blood glucose (6) . Thus, GLP-1 was proposed as one of the mediators of the enteroinsular axis in man (6) .
Recently, two biologically active peptides, exendin 3 and 4, differing only at amino acid positions 2 and 3, have been isolated from helodermatidae venom (13, 14) . Exendin 4 was found to bind avidly to the GLP-1 receptor and its fragment, exendin , to be an antagonist at this receptor (15, 16) . The latter provided a potential tool to assess the importance of GLP-1 in the entero-insular axis. We determined the specificity and GLP-1 inhibitory ratio of exendin (9-39) using in vitro receptor studies. The in vivo action of exendin (9-39) on glucose-, arginine-, GIP-, and VIP-induced insulin release was examined in the anaesthetized rat. The effect of exendin (9-39) on postprandial insulin release was investigated in the conscious rat. Exendin (9-39) appeared an effective GLP-1 antagonist without action on arginine and glucose triggered insulin release or known insulin secretagogues other than GLP-1. A dramatic reduction of postprandial insulin release was seen in the conscious rat, strongly suggesting a physiological role for GLP-1 as a hormonal mediator of the entero-insular axis.
Methods
Receptor binding assays Peptide iodination. All peptides were iodinated by the iodogen ( 1,3,4,6,-tetrachloro-3a,6a-diphenylglycoluril; Pierce, Rockford, IL) method (17) . GLP-1 (3 nmols) (CRC, Harrow, UK) in 10 ,ul of 0.2 M phos-1. Abbreviations used in this paper: GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-l City, UK), 91 jig/ml fentanyl citrate and 2.5 mg/ml fluanisone (Hypnorm, Janssen, Oxford, UK), and maintained with further 0.25 ml doses. Cannulae (0.63 mm outer diameter; Portex, Hythe, UK) were placed in a femoral vein for infusion of peptides and in a femoral artery for blood sampling, and were kept patent with flushes of saline containing 50 U/ml heparin. After a 20-min run-in period of a continuous infusion of saline, peptides were infused over 2 min in a solution of 1% glucose and 5% rat plasma in saline. Blood samples (0.5 ml) were taken at -5, 0, 2, 4, 6, 10, and 20 min. Blood glucose concentration was measured using Glucostix (Ames, Basingstoke, UK) and a Glucometer II (Ames). Plasma insulin concentrations were measured by radioimmunoassay, (23 Interaction of exendin (9-39) with non-GLP-1 secretagogues. To determine the specificity of action of exendin (9-39); 50% glucose (0.8 g/kg), VIP (0.8 nmol/kg) or GIP (0.8 nmol/kg) were infused from 0 to 2 min, with and without exendin (9-39) (4.5 nmol/kg), as above. Arginine (375 mg/kg) was infused from 2 to 4 min after saline or exendin (9-39) (4.5 nmol/kg), which were infused from 0 to 2 min. Exendin (9-39) was pre-infused in this circumstance to prevent any possibility of the arginine reacting chemically with exendin (9-39). Action of GLP-J in trained conscious fed rats
In pilot studies untrained rats showed stress responses to injection which altered their feeding and therefore variably altered glucose and insulin levels. Male Wistar rats (200-250 g) were therefore trained for 10 d before experimentation. They were fasted from 17:00 to 09:00 and saline (0.3 ml) was injected subcutaneously at 09:00 before feeding. After injection of saline, rats were exposed to chow for 30 min and then the chow was removed. At the end of ten days the rats were accustomed to the injection and were conditioned to eating quickly (consuming 5 g standard chow, within 30 min). After fasting from 17:00 the night before rats were injected subcutaneously at 09:00 with either saline (control group, n = 40) or exendin (9-39) (0.5 nmol/kg, n = 20). This dose was chosen to mimic the ratio we had used in anesthetized animals taking into account the known naturally occurring postperandial concentration of GLP. After the injection 20 of the fasted control rats were killed (time minus 30 min). The exendin (9-39) treated group and the rest of the control group were exposed to food for 30 minutes, following which food was withdrawn, in an identical manner to the procedure carried out during training. 15 min and 45 min after the end of the meal 10 animals from each of the saline treated and exendin (9-39) treated groups were killed by intraperitoneal pentobarbitone overdose and blood rapidly collected by cardiac puncture. Measurements of plasma insulin, and blood glucose were made on the -30-, 15-, and 45-min blood samples. Plasma GLP-1 levels were measured in the 15-min samples.
Statistical analysis
All results are given as mean±SEM. Statistical analysis was performed by one way analysis of variance for each peptide separately. The effect of the experimental peptides were compared to control rats using repeated measures ANOVA of the data (24). A P value of less than 0.05 was considered to be statistically significant.
Results
Receptor binding assay Effects of GLP-J and exendin (9-39) on '251-GLP binding in RIN SAH membranes. Competition curves were constructed to determine the relative affinities of GLP-1 and its antagonist exendin (9-39) for GLP-1 receptors (Fig. 1) . GLP-1 showed an ICs of 0.36±0.04 nM for the GLP-1 receptor compared with an IC50 of 3.44±0.30 nM for exendin . Thus GLP-1 has an approximately 10-fold higher affinity than exendin (9-39) at this site.
Effects of exendin (9-39) on binding ofpeptides related to GLP-I. To investigate if exendin (9-39) was a specific antago- nist for GLP-1 receptors, we examined its effect on binding of three related peptides which also increase insulin secretion from the /3-cell, namely glucagon, VIP and PACAP. At concentrations of up to 10-6 M no competition by exendin (9-39) for binding sites of '"I-labeled glucagon, VIP, or PACAP was observed (results not shown).
Fasted anaesthetized rats Dose ranging study of GLP-1. There was no significant difference between baseline insulin levels in the five groups of animals. At 2 min after completion of the GLP-1 (0.1, 0.2, 0.3, and 0.4 nmol/kg) infusion there was a significant increase in plasma insulin (498±48, 925±36, 1784±73, and 2024±47 pmol/l) as compared to control (214±78 pmol/l, P < 0.01) (Fig. 2) . The insulin levels remained elevated in a dose related manner at 4 and 6 minutes, but had returned to baseline levels by 10 min.
Dose ranging study of exendin (9-39) with GLP-J. There was no significant difference between baseline insulin levels in the four groups of animals. When GLP-1 (0.3 nmol/kg) was infused in combination with three doses of exendin (9-39) (1.5 nmol/kg, 3.0 nmol/kg, 4.5 nmol/kg) there was a dramatic and highly significant dose-dependent decrease in insulin levels at 2 min (1288±75 pmol/l, 416±56 pmol/l, 233±38 pmol/l, P < 0.001), compared with GLP-l (0.3 nmol/kg) alone (1784±73 pmol/l) (Fig. 2) . This dose-dependent effect was similarly evident at 4 and 6 min. Exendin (9-39) alone. There was no significant effect of exendin (9-39) (4.5 nmol/kg) on insulin levels when exendin (9-39) was infused alone (262±48 pmol/l) compared with control (214±35 pmol/l). The glucose concentrations did not alter.
Exendin (9-39) plus arginine or glucose. To investigate if there was any nonspecific effect of exendin (9-39) on 3-cell function, arginine was infused with and without exendin (9-39). Arginine alone caused a significant increase in insulin concentration from a basal insulin value of 86±41 to 1428±178 pmol/l immediately after the infusion of arginine. The insulin concentration remained elevated for the following 16 min. When exendin (9-39) and arginine were infused there was no significant difference in the insulin response when compared to arginine alone, (peak insulin with exendin was 1440±107 pmol/l compared with value above) (Fig. 3) .
The glucose mediated increase in insulin peaked at 1346±77 pmol/l compared with peak insulin level of 1399±24 pmol/l with glucose plus exendin (9-39) (not significant).
Exendin plus peptide secretagogues (VIP, GIP). The coadministration of exendin (9-39) at 4.5 nmol/kg had no effect on the concentration or time course of the insulin response curve to GIP and VIP. Peak values at 2 min were, for GIP (0.8 nmol/ kg) alone 1156±27 pmol/l, GIP plus exendin (9-39) 1107±38 pmol/l, VIP (0.8 nmol/kg) alone 969±36 pmol/l, and VIP plus exendin (9-39) 961±29 pmol/l (Fig. 2) .
Conscious trained feeding rats
Blood glucose was significantly increased in the exendin (9-39) treated rats compared with the saline treated group at 15
Peptide (nmol/kg) (Fig. 4 a) . The insulin level was significantly decreased in the exendin (9-39) treated group compared with the saline treated group at 15 min (224±32 pmol/l vs 431±21 pmol/l, P < 0.001) and at 45 min (208±20 pmol/l vs 349±38 pmol/l, P < 0.01) (Fig. 4 b) . It should be noted that plasma GLP-1 levels at 15 min were unaffected by exendin (9- In the fasted anaesthetized rat model, exendin (9-39) alone had no effect on insulin levels, suggesting the absence of a partial agonist effect at the concentrations used here. It is possible that an agonist effect may become apparent at higher concentrations. However, exendin (9-39) had a dramatic effect on the action of GLP-1, completely abolishing the stimulation of insulin secretion at a concentration ratio of approximately 10:1. Exendin (9-39) did not influence glucose or arginine stimulated insulin secretion, suggesting that there was no non-specific effect on the (-cell. In the light of the known similarity of amino acid sequence of GIP and GLP-1 (25), and the proposed role of GIP in the entero-insular axis (4, 5) it was important to exclude any effect of exendin (9-39) on GIP-stimulated insulin secretion. Neither GIP nor VIP-stimulated insulin release was significantly influenced by concomitant administration of exendin , at a dose which completely abolished GLP-1 stimulated insulin release. Insulin and glucose concentrations after a meal in conscious trained rats. All rats were injected with pre-meal subcutaneous saline for 10 d beforehand. On the day of the experiment exendin (9-39) treated animals (dotted line) were given pre-meal subcutaneous exendin (9-39) (4.5 nmol/kg) and control animals (solid line) received premeal subcutaneous saline. Glucose concentrations were significantly higher (P < 0.001 ) and insulin concentration were reduced in the exendin treated animals (P < 0.001 at 15 min and P < 0.01 at 45 min).
In the conscious trained rat exendin (9-39) treatment considerably reduced postprandial insulin concentrations compared with the saline treated group. Endogenous GLP-1 thus appears to contribute to the physiological release of insulin in the postprandial period. The lower insulin levels occurred in spite of the glucose concentrations in the exendin (9-39) treated rats being significantly higher than the control group. This tendency to glucose intolerance suggests GLP-1 may be required to maintain postprandial glucose concentrations at an optimal level. GLP-1 has been shown to have three main physiological actions of relevance to postprandial glucose tolerance. It delays gastric emptying (26) , inhibits glucagon release (6) and stimulates insulin release (6, 7, 27 ). The latter two actions depend on the ambient glucose concentration (7, 8, 28 ). The inhibition of glucagon is of importance when glucose is low (and perhaps in patients with diabetes who have abnormal glucagon release), and the stimulation of insulin release when glucose is elevated, as after a meal. In the conscious rat experiments reported here, the effect of exendin 
